Aurinia Pharmaceuticals
AUPH
66 hedge funds and large institutions have $120M invested in Aurinia Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 7 closing their positions.
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
6% more capital invested
Capital invested by funds: $113M → $120M (+$7.03M)
3% more funds holding
Funds holding: 64 → 66 (+2)
0.58% less ownership
Funds ownership: 25.84% → 25.26% (-0.58%)
6% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 18
59% less call options, than puts
Call options by funds: $1M | Put options by funds: $2.42M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$3.3M |
| 2 |
A
Abingworth
London,
United Kingdom
|
+$827K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$644K |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
+$559K |
| 5 |
Franklin Resources
San Mateo,
California
|
+$384K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.96M |
| 2 |
O
OrbiMed
New York
|
-$2.56M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.16M |
| 4 |
D.E. Shaw & Co
New York
|
-$654K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$390K |
AUPH Hedge Fund Activity: Q2 2018 in Review
66 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q2 2018, worth a combined $120M — up 6.2% from $113M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new AUPH positions and 7 closed out — a net gain of 3 holders — while 17 added to existing stakes and 18 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $3.3M. The largest seller was Morgan Stanley, cutting an estimated $2.96M.
- 66 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q2 2018, up from 64 in Q1 2018.
- Funds reported $120M of Aurinia Pharmaceuticals stock for Q2 2018, up 6.2% quarter-over-quarter.
- 10 funds opened new Aurinia Pharmaceuticals positions in Q2 2018 and 7 closed out, a net change of +3 holders.
- The largest Aurinia Pharmaceuticals buyer in Q2 2018 was Goldman Sachs, an estimated $3.3M added.
- The largest Aurinia Pharmaceuticals seller in Q2 2018 was Morgan Stanley, an estimated $2.96M sold.
Based on aggregated 13F filings for Q2 2018.